Dr. Dimos was a founding scientist at the drug discovery platform technology company iPierian, which spun out True North Therapeutics. The two companies developed multiple clincal-stage assets and had ~$1.5 billion in exits. Before Fountain, Dr. Dimos helped launch and served as vice president at Mavericks Capital, an investment bank for early-stage life science companies developing new products in therapeutics, diagnostics, medical devices and digital health. He later became responsible for pipeline and portfolio diligence at the investment platform Propel(x) Inc., and he remains a member of the investment committee at the Propel(x) affiliated Newton Fund, syndicating and investing in biotech and AI startups.

Dr. Dimos completed a fellowship at Harvard, holds a Ph.D. from Princeton in molecular biology and a B.S. from Tufts University. His research studies have been cited by over 6,000 publications, and his work with stem cells was featured on the cover of Time Magazine.